BACE1 and Obesity: Inhibitory activities against the key enzymes relevant to obesity (lipase), diabetes (α-glucosidase and α-amylase), and Alzheimer’s disease (AChE, BChE, and BACE-1) and the nonenzymatic glycation reaction were also assessed.